Inmaculada R.

Focused on rare protein‑misfolding disorders, the investigator evaluates interventions for transthyretin amyloid cardiomyopathy (ATTR‑CM) and hereditary dilated cardiomyopathy, aiming to improve cardiac function and survival.

• Transthyretin amyloid cardiomyopathy
• Hereditary dilated cardiomyopathy
• Obstructive hypertrophic cardiomyopathy
• Symptomatic hypertrophic cardiomyopathy

Research integrates novel agents targeting amyloid deposition and myocardial remodeling.

In the oncology arena, the investigator concentrates on targeted therapies for non‑small cell lung cancer (NSCLC), especially RET‑fusion and KRAS‑mutated subsets, and on endocrine‑based regimens for HER2‑negative hormone‑receptor‑positive breast cancer.

• Non‑small cell lung cancer
• RET‑fusion positive NSCLC
• KRAS G12C mutated NSCLC
• HER2‑negative hormone‑receptor‑positive breast cancer

These studies seek to extend progression‑free survival and enhance disease‑specific outcomes.

The investigator’s hematology portfolio includes therapeutic advancement for multiple myeloma and acute myeloid leukemia (AML), with emphasis on measurable residual disease eradication and novel combination regimens.

• Multiple myeloma
• Acute myeloid leukemia
• Chronic lymphocytic leukemia
• Myelodysplastic syndrome

Efforts target deep remission and durable responses in high‑risk patient cohorts.

Within infectious disease research, the investigator contributes to optimizing antiretroviral strategies for human immunodeficiency virus (HIV), focusing on regimen simplification and neuropsychiatric safety.

• Human immunodeficiency virus
• Antiretroviral therapy
• Dolutegravir‑based regimens
• Bictegravir/Emtricitabine/Tenofovir alafenamide

These studies aim to sustain viral suppression while minimizing adverse effects.